OncoMatch/Clinical Trials/NCT04464759
A Study of Nivolumab and Hydroxychloroquine or Nivolumab/Ipilimumab and Hydroxychloroquine in Advanced Melanoma
Is NCT04464759 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies multiple treatments including Nivolumab and Hydroxychloroquine for melanoma.
Treatment: Nivolumab · Hydroxychloroquine · Ipilimumab — This study will evaluate the safety, tolerability and efficacy (objective response rate) of using hydroxychloroquine (HCQ) in combination with nivolumab and ipilimumab or with nivolumab alone in subjects with advanced/metastatic melanoma.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Other
Cancer type
Melanoma
Biomarker criteria
Allowed: PD-L1 (CD274) any tested
any programmed death-ligand 1 (PD-L1) immunohistochemistry (IHC) status
Disease stage
Required: Stage III, IV
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: immunotherapy
Exception: Phase 2 Cohort 2a: prior immunotherapy required; Phase 2 Cohort 2b: anti-PD-1 Ab-naïve only; Phase 1b: anti-PD-1 refractory required
Phase 2 nivolumab + HCQ Cohort B: No prior immunotherapy is permitted
Cannot have received: active immunotherapy, chemotherapy, or investigational anticancer therapy
Exception: must be discontinued >= 4 weeks prior to study entry (oral targeted therapy >= 2 weeks)
Must have discontinued active immunotherapy, chemotherapy, or investigational anticancer therapy at least 4 weeks prior to entering the study and oral targeted therapy at least 2 weeks prior to entering the study.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Abramson Cancer Center at University of Pennsylvania · Philadelphia, Pennsylvania
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT04464759 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior immunotherapy, active immunotherapy, chemotherapy, or investigational anticancer therapy disqualifies patients from enrollment.
What disease stage is eligible?
Stage III or IV is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages